BlueRidge Scientist Dr. Naomi Sacks Co-Authors High-Impact Study on Obesity Outcomes

We’re proud to recognize the work of Dr. Naomi Sacks, Vice President, Pharmaceutical Commercialization at BlueRidge Life Sciences, whose recent study has earned a place among the top 10% most-viewed articles published by Obesity Science & Practice in 2023.

Conducted on behalf of The Obesity Society, the study leveraged national survey data to examine how overweight and obesity affect clinical outcomes, economic burden, and health-related quality of life in the United States. The findings reveal a strong association between excess weight and a range of challenges including obesity-related comorbidities, decreased mobility and productivity, increased disability, and reduced quality of life. The study also identified an important gap in care: very low usage of anti-obesity medications during the study period.

This work reflects the caliber of scientific insight and real-world evidence that BlueRidge is proud to deliver across every phase of the therapeutic development lifecycle.

Read the full open-access article: Clinical, economic, and health‐related quality of life outcomes in patients with overweight or obesity in the United States: 2016–2018